The stock may react positively to the strengthened balance sheet and strategic focus on NXT-41x, but traders should monitor whether declining core revenue can be reversed with the new product launch. The release of $8.0 million in escrow in Q4 2026 provides a future cash milestone.
ELUT drugs
ELUT drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 12 $1.15entry
- T+1 · 8mo ago −6.09%α −5.49% · $1.08
- T+5 · 8mo ago −8.70%α −7.72% · $1.05
- T+20 · 7mo ago −1.74%α −3.71% · $1.13
- T+60 · 5mo ago −13.13%α −23.83% · $0.9990
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Elutia reported its 2025 financial results, highlighted by the $88 million sale of its BioEnvelope business to Boston Scientific, which generated a net income of $53.4 million for the year. The company strengthened its balance sheet, repaid $26.9 million in debt, and now holds $44.4 million in cash and escrow. It also advanced its NXT-41x development program and initiated a strategic review of its SimpliDerm product line to focus on upcoming commercialization.
Key Financial Metrics
Key Facts
- Closed $88 million sale of BioEnvelope business to Boston Scientific in Q4 2025
- Full-year 2025 net income was $53.4 million (vs. $53.9 million net loss in 2024), driven by the gain on divestiture
- Full-year 2025 revenue from continuing operations declined 15.2% to $12.3 million (from $14.5 million)
- Company repaid $26.9 million in debt and ended 2025 with $36.4 million in cash and $8.0 million in escrow
- NXT-41 regulatory submission made; clearance expected in second half of 2026
- Initiated strategic process to explore options for SimpliDerm product line
Financial Impact
Revenue from continuing operations declined 15.2% YoY to $12.3 million in 2025, while net income turned positive at $53.4 million due to $88 million gain on divestiture
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| SimpliDerm | $9.1M | -21.6% |
| Cardiovascular | $3.2M | +10.3% |
Risk Factors
- Core revenue (continuing operations) declined significantly in 2025
- Future performance now heavily dependent on successful launch of NXT-41x
- Strategic review of SimpliDerm introduces uncertainty around that product line
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-026398 |
| Document: elut-20260303x8k.htm | 0001104659-26-026398 |
| Document: 0001104659-26-026398-index-headers.html | 0001104659-26-026398 |
| Document: 0001104659-26-026398-index.html | 0001104659-26-026398 |
| Document: 0001104659-26-026398.txt | 0001104659-26-026398 |
Track record
7 reports on ELUT
Filters
- Nov 5, 202611d ago Press Release Neutral 4/10 No price data
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $0.8374 Now $0.8230 −1.72% settles Dec 7
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $0.8615 Now $0.8230 −4.47% settles Nov 20
- Jul 31, 202615w ago Press Release Neutral 1/10 Entry $0.8568 to $0.8800 Now $0.8230 −3.94% ▲ +2.71% −0.28% vs SPY
- Jun 16, 202621w ago 8-K Neutral 3/10 Entry $0.9914 to $0.9500 Now $0.8230 −16.99% ▼ −4.18% −5.49% vs SPY
- May 14, 202626w ago 8-K Neutral 5/10 Entry $1.03 to $0.9690 Now $0.8230 −20.10% ▼ −5.92% −8.04% vs SPY
- Mar 11, 202635w ago 8-K Mixed 7/10 Viewing Entry $1.15 to $1.13 Now $0.8230 −28.43% ▼ −1.74% −3.71% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers